Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung ...

Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...

Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...

Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer ...

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

Johnson & Johnson said its combination therapy for lung cancer outperformed AstraZeneca Plc’s blockbuster Tagrisso in a ...

By Bhanvi Satija (Reuters) -Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful ...

Johnson & Johnson's Rybrevant and Lazcluze combination shows significant overall survival benefits over Tagrisso in the ...

Johnson & Johnson said its recently approved Rybrevant and Lazcluze combination therapy topped Tagrisso on overall survival ...

An AI system developed to predict a patient's response to immunotherapy could help "democratize" access to the pricey drugs ...

First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or ...